Zacks Research Expects Lower Earnings for Colgate-Palmolive

Colgate-Palmolive Company (NYSE:CL) – Analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Colgate-Palmolive in a research note issued to investors on Friday, February 13th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $0.95 for the quarter, down from their prior estimate of $0.96. The consensus estimate for Colgate-Palmolive’s current full-year earnings is $3.75 per share. Zacks Research also issued estimates for Colgate-Palmolive’s Q2 2026 earnings at $0.97 EPS, Q4 2026 earnings at $1.00 EPS, FY2026 earnings at $3.89 EPS, Q1 2027 earnings at $1.03 EPS, Q2 2027 earnings at $1.03 EPS, Q3 2027 earnings at $1.02 EPS, Q4 2027 earnings at $1.06 EPS, FY2027 earnings at $4.15 EPS and FY2028 earnings at $4.44 EPS.

Several other analysts have also recently weighed in on CL. Jefferies Financial Group boosted their price objective on Colgate-Palmolive from $85.00 to $91.00 and gave the stock a “hold” rating in a report on Monday, February 2nd. Wells Fargo & Company lifted their target price on shares of Colgate-Palmolive from $86.00 to $94.00 and gave the stock an “equal weight” rating in a report on Sunday, February 1st. Raymond James Financial cut their price target on Colgate-Palmolive from $105.00 to $95.00 and set an “outperform” rating on the stock in a research note on Monday, October 20th. Royal Bank Of Canada upgraded Colgate-Palmolive from a “sector perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a research report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. upped their price objective on Colgate-Palmolive from $93.00 to $97.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Eleven research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $94.38.

Colgate-Palmolive Stock Performance

CL stock opened at $96.61 on Monday. The company has a 50 day moving average price of $83.80 and a 200 day moving average price of $81.84. Colgate-Palmolive has a fifty-two week low of $74.54 and a fifty-two week high of $100.18. The company has a debt-to-equity ratio of 5.90, a current ratio of 0.42 and a quick ratio of 0.27. The stock has a market capitalization of $77.87 billion, a PE ratio of 36.87, a price-to-earnings-growth ratio of 4.36 and a beta of 0.29.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings results on Friday, January 30th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.04. The business had revenue of $5.23 billion for the quarter, compared to the consensus estimate of $5.13 billion. Colgate-Palmolive had a net margin of 10.45% and a return on equity of 353.72%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.91 EPS.

Colgate-Palmolive Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Wednesday, January 21st were issued a $0.52 dividend. The ex-dividend date was Wednesday, January 21st. This represents a $2.08 annualized dividend and a dividend yield of 2.2%. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 79.39%.

Insider Buying and Selling

In other news, insider John Hazlin sold 20,989 shares of the stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $94.25, for a total value of $1,978,213.25. Following the completion of the sale, the insider owned 17,645 shares of the company’s stock, valued at approximately $1,663,041.25. This represents a 54.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Stanley J. Sutula III sold 97,843 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $94.27, for a total transaction of $9,223,659.61. Following the completion of the transaction, the chief financial officer directly owned 55,310 shares of the company’s stock, valued at $5,214,073.70. This represents a 63.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 184,683 shares of company stock worth $17,486,693 in the last three months. Insiders own 0.41% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CL. Jacobi Capital Management LLC raised its holdings in shares of Colgate-Palmolive by 5.8% in the 4th quarter. Jacobi Capital Management LLC now owns 10,543 shares of the company’s stock valued at $833,000 after purchasing an additional 581 shares during the period. CreativeOne Wealth LLC increased its position in Colgate-Palmolive by 7.6% during the fourth quarter. CreativeOne Wealth LLC now owns 16,087 shares of the company’s stock worth $1,271,000 after buying an additional 1,140 shares during the last quarter. Kestra Advisory Services LLC increased its position in Colgate-Palmolive by 2.2% during the fourth quarter. Kestra Advisory Services LLC now owns 40,463 shares of the company’s stock worth $3,197,000 after buying an additional 885 shares during the last quarter. Ontario Teachers Pension Plan Board raised its stake in Colgate-Palmolive by 7.3% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 40,234 shares of the company’s stock valued at $3,179,000 after buying an additional 2,732 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Colgate-Palmolive by 2.2% in the fourth quarter. The Manufacturers Life Insurance Company now owns 816,427 shares of the company’s stock valued at $64,689,000 after buying an additional 17,771 shares during the last quarter. Institutional investors own 80.41% of the company’s stock.

Key Stories Impacting Colgate-Palmolive

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Zacks Research raised several forward earnings estimates (including FY2026 to $3.89 and FY2027 to $4.15) and lifted some quarterly targets, signaling better-than-expected longer‑term earnings progression — supportive for valuation upgrades. Zacks estimate revisions (MarketBeat)
• Positive Sentiment: Major brokers have recently raised targets and stance (Morgan Stanley to $100/overweight; JPMorgan to $97/overweight; Wells Fargo nudged its target higher), which can attract buying and help lift the stock. Analyst target changes (MarketBeat)
• Positive Sentiment: Media/TV mention — Jim Cramer highlighted Colgate’s strong growth, a visible endorsement that can spur retail interest and intraday buying. Cramer: Colgate had great growth
• Neutral Sentiment: Dividend and shareholder returns remain intact — Colgate paid the routine $0.52 quarterly dividend (annualized $2.08, ~2.2% yield); supportive for income investors but already priced in for many holders. Dividend announcement (MarketBeat)
• Neutral Sentiment: Institutional activity shows small incremental buys by several funds in Q4 (some managers added to positions), indicating steady institutional ownership (~80% held by institutions). That steady demand can limit downside but isn’t a near-term catalyst. Institutional flows (MarketBeat)
• Negative Sentiment: Significant insider selling: COO Panagiotis Tsourapas sold 15,000 shares (~$1.47M at ~$97.81), reducing his stake materially. Large insider sales can concern investors about timing or personal liquidity needs and may create short‑term selling pressure. COO Panagiotis Tsourapas sells 15,000 shares
• Negative Sentiment: Another insider (John Hazlin) sold ~20,989 shares for ~$1.98M. Multiple insider sales over days amplify the negative signal versus isolated transactions. Investors should watch future filings for patterns. Insider sale: John Hazlin

About Colgate-Palmolive

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.